The Influence of Probiotic Supplementation on the Severity of Anxiety and Depressive Symptoms, as Well as the Function and Composition of Gut Microbiota, Metabolic, Inflammation, and Oxidative Stress Markers in Patients With Depression
NCT ID: NCT05717946
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
100 participants
INTERVENTIONAL
2021-01-04
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The designed study will be prospective, randomized, placebo-controlled, and double-blind. The intervention period will last 8 weeks for each patient. The study will be conducted on 100 patients in total, who will be randomly divided into two groups, consisting of 50 patients each.
Patients included in Group I (PRO-D) will receive one capsule daily containing a probiotic mixture at a daily dose of 3×109 colony-forming units (CFU). The probiotic will be composed of two bacteria strains: Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell, made of hydroxypropylmethylcellulose.
Patients included in Group II (PLC-D) will receive daily the same capsule, containing only excipients: potato starch, maltodextrin, and the capsule shell. The color, smell, and taste of the placebo will not be different from those included in the probiotic capsule.
Patients will be considered compliant if they consume \>= 80% of the supplements.
The primary outcome measures will be the severity of depressive anxiety and stress symptoms assessed with Montgomery-Åsberg Depression Rating Scale (MADRS) and the Depression, Anxiety, Stress Scale (DASS) with subscales scores, the quality of life level assessed with the WHOQOL-BREF instrument. The secondary outcomes measures will include: blood pressure (BP), body mass index (BMI) and waist circumference (WC) measures, fasting glucose (fGlc), HDL cholesterol (HDL-C), triglycerides (TG), white blood cells count (WBC), neutrofiles, serum levels of C-reactive protein (CRP), the level of faecal SCFAs, faecal microbiota α-diversity and the level of oxidative stress parameters (total antioxidant capacity (TAC) and malondialdehyde (MDA)) in the blood serum.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity
NCT04756544
The Effect of Probiotic Supplementation on Mental Health in Healthy Volunteers
NCT06391216
The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients
NCT02838043
Efficacy and Safety of Probiotics for Anxiety Depression
NCT07331987
Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression
NCT02035878
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I "PRO-D"
50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
Group II "PLC-D"
50 patients with diagnosed depressive disorders, meeting the criteria of International Classification of Diseases (ICD-11) for 6A70-73, 6A7Y, 6A7Z, taking a placebo.
control group
We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
control group
We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 18 - 70 years,
3. MADRS score \>=13,
4. Antidepressant and antianxiety medications not changed 3 weeks prior to the recruitment visit.
Exclusion Criteria
2. An infection/vaccination and/or treatment with antibiotics in the previous 4 weeks,
3. Supplementation with pro- or prebiotics in the previous 4 weeks,
4. Having a diagnosis of autoimmune, serious immunocompromised, inflammatory bowel diseases, cancer, IgE-dependent allergy, or severe kidney failure in the previous 4 weeks,
5. body mass index (BMI)\> 35,
6. glomerular filtration rate (GFR)\< 30 ml/min/1,72 m2,
7. unstable thyroid dysfunction (TSH \< 0,27 or \> 4,2 μIU/ml) in the previous 4 weeks,
8. Psychiatric comorbidities (except specific personality disorder, additional specific anxiety disorder, and caffeine, and nicotine addiction),
9. Regular treatment (more than 3 days a week) with PPIs, metformin, laxatives, systemic steroids, or NSAIDs in the previous 4 weeks,
10. Significant change in dietary pattern in the previous 4 weeks,
11. Significant change in daily physical activity or extreme sports activity in the previous 4 weeks,
12. Significant change in dietary supplementation in the previous 4 weeks,
13. Significant change in smoking pattern in the previous 4 weeks,
14. High risk of suicide,
15. Is participating in, or has recently participated in, another research study involving an intervention that may alter outcomes of interest to this study,
16. Any other condition or situation which, in the view of investigators, would affect the compliance or safety of the individual taking part.
Reasons for the participant to be discontinued from the study:
1. Withdrawal of informed consent,
2. An infection/vaccination and/or treatment with antibiotics during the trial,
3. Consuming any other than studied probiotics during the trial,
4. Lack of compliance with the probiotic supplementation,
5. Any change in the drug regimen during the study,
7. Any serious adverse event during the trial.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Lodz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dominik Strzelecki
Professor, MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominik Strzelecki, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Medical University of Lodz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Teaching Hospital, Medical University of Lodz
Lodz, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MULodzAff_1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.